#Sweden #Lund #Hansa Biopharma #imlifidase #Cradle

Hansa Biopharma Collaborates with Cradle to Enhance Therapeutic Development

In a significant move towards revolutionizing treatment options for autoimmune diseases, Hansa Biopharma AB has announced a strategic partnership with Cradle, a company renowned for its cutting-edge AI-driven platform dedicated to protein design and engineering. This collaboration marks a pivotal step as Hansa aims to deploy Cradle's comprehensive technology to innovate and streamline the development of their therapeutic candidates, potentially transforming care for patients with severe autoimmune conditions.

Based in Lund, Sweden, Hansa Biopharma specializes in creating immunoglobulin G (IgG) related therapies, targeting rare immunologic disorders. The company's most notable product, imlifidase, known commercially as Idefirix, is a pioneering enzyme already on the market in Europe and is under FDA review for use in highly sensitized patients awaiting kidney transplants. The partnership with Cradle aims to leverage AI's capabilities in protein engineering to develop enhanced, effective treatment options for these vulnerable patients.

Sofia Järnum, Hansa's Vice President of Research and Early Development, explained the selection of Cradle for this transformative initiative. “We evaluated multiple AI platforms and vendors, but Cradle stood out due to its unique integration of essential capabilities for modern protein engineering,” she stated. These include comprehensive support throughout the discovery pipeline, adaptable multi-parameter optimization for complex engineering tasks, and a system that actively learns from Hansa’s existing data, ultimately resulting in more reliable and predictable outcomes.

The partnership highlights Hansa's commitment to investing in AI-driven processes for drug discovery. As the biopharmaceutical landscape grows increasingly competitive, utilizing Cradle's extensive expertise could afford Hansa a crucial edge in developing novel therapeutics efficiently. Notably, Cradle has established a solid track record with major biopharmaceutical firms, indicating its capabilities in producing substantial results for its partners. According to Cradle, organizations reporting the use of its platform have experienced development timelines accelerated by up to 18 months, translating into significant cost savings per clinical candidate.

Stef van Grieken, Co-Founder and CEO of Cradle, expressed enthusiasm about the collaboration, stating that the future of therapeutic engineering lies in empowering scientists with innovative platforms that evolve alongside them. “This partnership is crucial for Hansa’s ambition to speed up the discovery of high-quality therapeutics for patients suffering from severe autoimmune diseases,” he added.

Hansa’s innovative approach combines donor organs’ compatibility with high-risk patients, particularly those who are highly sensitized, and the collaboration with Cradle is aimed at extending this operational model by utilizing advanced AI technology. The implications of such advancements could profoundly affect the landscape of organ transplantation and autoimmune disorder treatments.

Moving forward, Hansa Biopharma aims to robustly integrate AI into its drug discovery workflows, harnessing Cradle’s technological capabilities to bring forward new therapeutic candidates designed to meet pressing medical needs. This partnership signifies a growing trend in the biotech and pharmaceutical sectors, emphasizing the importance of AI and machine learning in advancing research and development efforts in healthcare and therapeutics.

For those keen on following Hansa Biopharma’s journey, additional information about the company and its innovative product pipeline can be found on their official website at hansabiopharma.com or through their LinkedIn page.

This collaboration not only illustrates the accelerated pace of innovation in the biopharmaceutical landscape but also highlights the critical role that technology, particularly AI, plays in paving the way for breakthroughs in therapeutic development.

Conclusion

The partnership between Hansa Biopharma and Cradle exemplifies the transformative potential of AI in drug discovery and development. As Hansa pushes forward in its mission to address unmet medical needs in the realm of autoimmune diseases, this collaboration could very well signal a new era of innovation in biopharma therapy advancements, promising more effective and personalized treatment options for patients worldwide.